Results 251 to 260 of about 180,170 (299)

Assessment tools for peripheral neuropathy in multiple myeloma. [PDF]

Korean J Intern Med
Park SS, Kwak K, Baek SH, Kim C, Choi YS, Park Y, Kim BS, Kim JS, Min CK, Kang KW.   +9 more
europepmc   +1 more source

Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma

The FEBS Journal, EarlyView.
IMiDs are pivotal in the treatment of multiple myeloma. Mechanisms of resistance comprise cell intrinsic and extrinsic pathways, involving tumour microenvironment, immune cell dysfunction, CRBN‐dependent and independent genetic drivers and epigenetic changes.
Maria‐Cynthia Fuentes‐Lacouture, Devi Nandana, Karthik Ramasamy, Anjan Thakurta   +3 more
wiley   +1 more source

Incidental discovery of acquired factor X deficiency in a patient with multiple myeloma. [PDF]

Leuk Res Rep
Sbibih Y, Bensalah M, Saddari A, Slaoui M, Trougouty N, Berhili A, Seddik R.   +6 more
europepmc   +1 more source

Stimulating proteasomal degradation in human proteinopathies

The FEBS Journal, EarlyView.
The proteasome mediates the degradation of a wide range of proteins. Boosting proteasomal degradation may be beneficial in several disease contexts and can be achieved either by modulating proteasome activity or by improving substrate delivery. Proteasome activity can be enhanced by increasing proteasome abundance, inducing constitutive gate opening ...
Maria E. Gierisch, Enrica Barchi, Nico P. Dantuma   +2 more
wiley   +1 more source

Treatment Intensity in the Frontline Setting for Transplant-Ineligible Patients With Multiple Myeloma. [PDF]

J Adv Pract Oncol
Davis M.
europepmc   +1 more source

Enhanced dynamic risk stratification of smoldering multiple myeloma. [PDF]

Nat Med
Chabrun F, Schwartz DE, Gentile S, Mai EK, Gupta TR, Perry J, Cordas Dos Santos DM, Hielscher T, Werly A, Schmidt SK, Theodorakakou F, Fotiou D, Liacos CI, Kanellias N, Gisbert NC, Martin-Sanchez E, Termini R, Waldschmidt J, Chavda SJ, Ainley L, Da Vià MC, De Magistris C, Pettine L, Timonian MA, Alberge JB, Patel V, Costello P, Tobia C, Phan S, Lamb J, Silverio MT, Davis M, O'Donnell EK, Marinac CR, Nadeem O, Bolli N, Yong K, Kortüm KM, Einsele H, Mateos MV, Kumar S, San-Miguel JF, Paiva B, Kastritis E, Dimopoulos MA, Raab MS, Trippa L, Ghobrial IM.   +47 more
europepmc   +1 more source

Prognostic nutritional index, but not NLR or PLR, is linked to survival in multiple myeloma. [PDF]

Front Oncol
Keni Begendi N, Duran M, Culha Y.
europepmc   +1 more source

How Laboratory Innovations Are Shaping the Future of Multiple Myeloma Care. [PDF]

Cancers (Basel)
Caetano J, Pires AM, Costa C, Bergantim R, Roque A, Ferraz P, Cunha MR, Bolli N, Puig N, João C.   +9 more
europepmc   +1 more source